Immunocore Holdings PLC at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jessica Fye. I'm a biotech analyst at J.P. Morgan, and we're continuing the 44th Annual Healthcare Conference today with Immunocore.
First, you're going to hear a presentation from the company, and then we're going to go into a Q&A session. So if you're in the room and want to ask a question, just raise your hands. I'm going to bring you a microphone. And if you're listening online, you can submit questions to the portal, and I'll read them off the iPad up here.
So with that out of the way, let me turn it over to Immunocore CEO, Bahija Jallal.
Good morning and thank you, Jess, for having us. It's always a pleasure. This is our forward-looking statement. Our mission at Immunocore is to bring transformative medicines to patients. We are a commercial stage biotechnology company that pioneered the first soluble TCR receptor bispecific platform. This platform is validated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
